𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

✍ Scribed by Somaia Mohamed; Robert Rosenheck; Ilan Harpaz-Rotem; Douglas Leslie; Michael J. Sernyak

Book ID
106506657
Publisher
Springer US
Year
2009
Tongue
English
Weight
195 KB
Volume
80
Category
Article
ISSN
0033-2720

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term treatment with long-acting ris
Long-term treatment with long-acting risperidone in Korean patients with schizophrenia
✍ Moon-Soo Lee; Young-Hoon Ko; Sang-Hoon Lee; Yong-Jin Seo; Seung-Hyun Kim; Sook-H 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

## Abstract ## Objectives We evaluated the efficacy and safety of long‐acting risperidone for 48‐week period in Korean patients. ## Methods This was a non‐randomized, open‐label, single‐centered, 48‐week study. Each of the participants visited the hospital every 2 weeks, and injections were give

Remission in schizophrenia: one-year Ita
Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder
✍ Alessandro Rossi; Anna Bagalà; Vincenzo Del Curatolo; Francesco Scapati; Micaela 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 1 views

## Abstract ## Objectives To evaluate the maintenance of efficacy of risperidone long‐acting injectable (RLAI) in stable patients with schizophrenia or schizoaffective disorders. The prevalence of patients who met standardized remission criteria will be also evaluated as well as the predictors fac

Effects of switching to long-acting inje
Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia
✍ Sung-Wan Kim; Il-Seon Shin; Jae-Min Kim; Seung-Hyun Lee; Yo-Han Lee; Su-Jin Yang 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## Abstract ## Objective To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long‐acting injectable risperidone (LAIR) in patients with schizophrenia. ## Methods Thirty‐six patients with schizophrenia treated with oral